Newland Pharmaceutical Co., Ltd. (301277.SZ)
Key Executives
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Luwei Zhang | GM & Director | -- | -- | 1971 |
Mr. Chao Liu | Deputy GM, Chief Engineer & Director | -- | -- | 1986 |
Newland Pharmaceutical Co., Ltd.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 1,042
Description
Newland Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates and APIs in China. The company offers pharmaceutical intermediates, including L-4-hydroxyphenylglycine methyl ester, L-hydroxyphenylglycine potassium salt, L-4-hydroxyphenylglycine, and p-Toluenesulfonic acid. It also provides APIs, such as ropivacaine hydrochloride, naphazoline hydrochloride, moxifloxacin hydrochloride, lidocaine hydrochloride, vildagliptin, tadalafil, chlorpheniramine maleate, clopidogrel bisulfate, lidocaine, gatifloxacin, febuxostat, esomeprazole sodium, and esomeprazole magnesium. The company was formerly known as Henan Newland Pharmaceutical Co., Ltd. and changed its name to Newland Pharmaceutical Co., Ltd. in June 2023. Newland Pharmaceutical Co., Ltd. was founded in 2005 and is based in Changge City, China.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
April 16, 2025 at 12:00 AM UTC
Ex-Dividend Date